Orchid Pharma — 360° view

Orchid Pharma, a company in the Pharmaceuticals industry, reported revenue of ₹341 crore and net profit of ₹29 crore for the September 2026 quarter.

Orchid Pharma (NSE: ORCHPHARMA) closed at ₹960.40 on 20 Nov 2026, up 10.4% over the past year. Its market capitalisation is ₹5,751 crore and it trades at 109.8 times earnings.

Share price
₹960.40 (20 Nov 2026)
Market cap
₹5,751 Cr (20 Nov 2026)
P/E
109.82 (20 Nov 2026)
Revenue
₹341 Cr (September 2026 quarter)
Net profit
₹29 Cr (September 2026 quarter)
ROCE
1.86% (FY26)
ROE
1.49% (FY26)
Book value
₹273 (FY26)
Dividend yield
0.00% (last 12 months to 20 Nov 2026)
52-week high / low
₹1,143.50 / ₹480.00 (20 Nov 2026)
1-year return
10.4% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: ORCHPHARMA

Orchid Pharma is a pharmaceutical company engaged in the development and manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms. It is also engaged in research of new drugs.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.